acute myeloid leukemia

Six diseases reap benefits of biomarkers, genetic tests
Six diseases reap benefits of biomarkers, genetic testsBiomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening.
Midostaurin extends survival among some AML patients: StudyAML’s genetic complexity raises concerns about long-term prospects of single mutation-targeting agents
FDA drug approvals-January 2015FDA actions in brief, recommendations for approval, fast-track designations.
February FDA drug approvalsFDA actions in brief, complete response, breakthrough therapy designation, fast-track designation